Charles Russell Speechlys advises on three secondary fundraises across three different markets
Charles Russell Speechlys has advised on three secondary fundraises across three different markets (Main Market, AIM and AQSE) in a month.
The team acted for Panmure in its role as Joint Bookrunner, Corporate Broker and Corporate Adviser on a £6 million fundraise for AQSE listed Equipmake plc. Equipmake is a UK-based engineering specialist pioneering the development and production of electrification products across the automotive, aerospace, bus, and coach industries.
This was followed up shortly afterward as the team were called on to act for Allenby Capital in its role as broker on a £1.375 million fundraise for AIM listed Fusion Antibodies plc. Fusion Antibodies specialises in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications.
Most recently, the team advised Main Market listed HeiQ plc, a leading company in materials innovation and hygiene technologies on a £2.44 million fundraise and convertible loan note issue.
Paul Arathoon, Corporate Partner, commented:
“It was a pleasure to act on a diverse set of fundraises to support the strategic ambitions of the issuers. There is a lot of life in the market, and we look forward to seeing how these injections of capital help support the on-going growth ambitions of Equipmake, Fusion Antibodies, and HeiQ.”
The deal teams were led by Corporate Partner Paul Arathoon, with support from Senior Associate Emily Dobson, and Trainees Andrew Blyth and Isobel Asti.
